[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IN2014KN00849A - - Google Patents

Info

Publication number
IN2014KN00849A
IN2014KN00849A IN849KON2014A IN2014KN00849A IN 2014KN00849 A IN2014KN00849 A IN 2014KN00849A IN 849KON2014 A IN849KON2014 A IN 849KON2014A IN 2014KN00849 A IN2014KN00849 A IN 2014KN00849A
Authority
IN
India
Prior art keywords
compounds
prophylaxis
pain
disorders
formula
Prior art date
Application number
Inventor
Foltyn Robert Frank
Thomas Christoph
Klaus Schiene
Vry Jean De
Nils Damann
Bernhard Lesch
Gregor Bahrenberg
Derek John Saunders
Hannelore Stockhausen
Yong Soo Kim
Myeong Seop Kim
Jeewoo Lee
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of IN2014KN00849A publication Critical patent/IN2014KN00849A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)

Abstract

The invention relates to substituted pyrazolyl based carboxamide and urea derivatives of formula (Q) as vanilloid receptor ligands to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
IN849KON2014 2011-11-09 2012-11-08 IN2014KN00849A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11008914 2011-11-09
PCT/EP2012/072140 WO2013068461A1 (en) 2011-11-09 2012-11-08 Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an o-containing group as vanilloid receptor ligands

Publications (1)

Publication Number Publication Date
IN2014KN00849A true IN2014KN00849A (en) 2015-10-02

Family

ID=47143122

Family Applications (1)

Application Number Title Priority Date Filing Date
IN849KON2014 IN2014KN00849A (en) 2011-11-09 2012-11-08

Country Status (14)

Country Link
EP (1) EP2776398B1 (en)
JP (1) JP6189313B2 (en)
KR (1) KR101985442B1 (en)
CN (2) CN103889961A (en)
AR (1) AR088702A1 (en)
AU (1) AU2012334065B2 (en)
BR (1) BR112014011262B1 (en)
CA (1) CA2854932A1 (en)
ES (1) ES2823577T3 (en)
HK (1) HK1201839A1 (en)
IN (1) IN2014KN00849A (en)
MX (1) MX2014005610A (en)
TW (1) TW201326133A (en)
WO (1) WO2013068461A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016096140A1 (en) * 2014-12-19 2016-06-23 Grünenthal GmbH Process for the preparation of 1-[(heteroaryl)-methyl]- or 1-[(aryl)-methyl]-3-[4-(hydroxymethyl)-phenyl]-ureas
JPWO2017170884A1 (en) * 2016-03-31 2019-02-14 富士フイルム富山化学株式会社 Process for producing novel hydroxamic acid derivatives and intermediates thereof
CN113135856B (en) * 2021-04-08 2022-10-11 天津大学 3-trifluoromethyl-5-cyanopyrazole compounds and preparation method thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8998598A (en) * 1997-09-11 1999-03-29 Nissan Chemical Industries Ltd. Pyrazole compounds and plant disease control agent
US20050171171A1 (en) * 2003-11-13 2005-08-04 Ambit Biosciences Corporation Amide derivatives as FLT-3 modulators
JP2005314407A (en) * 2004-03-31 2005-11-10 Nippon Nohyaku Co Ltd New haloalkylsulfonanilide derivative, herbicide, method for using the same and intermediate therefor
PE20110285A1 (en) * 2005-10-19 2011-06-04 Gruenenthal Chemie SULFONAMIDOPHENYL PROPIONAMIDE DERIVATIVES AS LIGANDS OF THE VANILOID RECEPTOR SUBTYPE 1
AU2007333194A1 (en) * 2006-12-08 2008-06-19 Exelixis, Inc. LXR and FXR modulators
DE102007018151A1 (en) * 2007-04-16 2008-10-23 Günenthal GmbH Novel vanilloid receptor ligands and their use in the preparation of medicines
US8592471B2 (en) * 2009-05-07 2013-11-26 Gruenenthal Gmbh Substituted phenylureas and phenylamides as vanilloid receptor ligands
BRPI1011192A2 (en) * 2009-05-07 2016-03-15 Gruenenthal Gmbh substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands, pharmaceutical composition, use and process for preparing said derivatives
MX2012010011A (en) * 2010-03-01 2012-10-05 Myrexis Inc Compounds and therapeutic uses thereof.

Also Published As

Publication number Publication date
WO2013068461A1 (en) 2013-05-16
AU2012334065B2 (en) 2017-06-08
JP6189313B2 (en) 2017-08-30
BR112014011262A2 (en) 2017-04-25
CA2854932A1 (en) 2013-05-16
AU2012334065A1 (en) 2014-05-22
JP2014532741A (en) 2014-12-08
CN103889961A (en) 2014-06-25
CN107739338A (en) 2018-02-27
KR20140091043A (en) 2014-07-18
BR112014011262B1 (en) 2022-02-15
EP2776398A1 (en) 2014-09-17
HK1201839A1 (en) 2015-09-11
KR101985442B1 (en) 2019-06-03
EP2776398B1 (en) 2020-09-02
BR112014011262A8 (en) 2018-03-06
MX2014005610A (en) 2014-07-30
AR088702A1 (en) 2014-06-25
ES2823577T3 (en) 2021-05-07
TW201326133A (en) 2013-07-01

Similar Documents

Publication Publication Date Title
MX2014000779A (en) Substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands.
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
NZ708593A (en) Novel pyrazole derivative
MX2014000964A (en) Substituted heterocyclic aza derivatives.
MX367623B (en) Substituted 6-amino-nicotinamides as kcnq2/3 modulators.
PH12015501964A1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
GEP20156285B (en) Compounds and compositions as trk inhibitors
MX2013011908A (en) Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors.
MX2013008296A (en) Diarylacetylene hydrazide containing tyrosine kinase inhibitors.
MY165113A (en) Piperidinone carboxamide azaindane cgrp receptor antagonists
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
WO2011107608A8 (en) Heterocyclic amides as rock inhibitors
NZ630830A (en) Benzamides
MX342924B (en) Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases.
IN2014MN00697A (en)
MX2013002118A (en) Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators.
MX2014000963A (en) Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands.
IN2013DN02555A (en)
MX2014003584A (en) Substituted methanesulfonamide derivatives as vanilloid receptor ligands.
MX342459B (en) Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators.
MX2014003455A (en) Aryl or n-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands.
IN2014KN00849A (en)
IN2014KN00865A (en)
MX2015005312A (en) 1 h-indole-3-carboxamide derivatives and use thereof as p2y12 antagonists.
IN2014KN00847A (en)